Clone:
HB5
Type of antibody:
Primary antibodies
Isotype:
mouse IgG2a
Alternative names:
Complement Receptor 2 (CR2), Complement 3d Receptor

Specifications for CD21 antibodies

Overview

HB5 recognizes CD21, a type I membrane glycoprotein. Expression of CD21 in humans is found on B cells, follicular dendritic cells, subsets of epithelial cells, and thymic T cells. The primary function attributed to CD21 has been to amplify the B cell receptor (BCR)-mediated signal transduction in response to antigen recognition. To enhance the BCR mediated activation, CD21 associates with CD19 and CD81 in a B cell–specific signal transduction complex, where interaction of BCR with CR2/CD19 amplifies the signals. In addition, CD21 serves as a receptor for split products of complement protein C3, the gp350/220 viral coat protein of the EBV and the immunoregulatory protein CD23.

Alternative names

Complement Receptor 2 (CR2), Complement 3d Receptor

Detailed product information

Technical specifications

CloneHB5
Isotypemouse IgG2a
Type of antibodyPrimary antibodies
Specieshuman
AntigenCD21
Alternative names of antigenComplement Receptor 2 (CR2), Complement 3d Receptor
Distribution of antigenB cells, dendritic cells, T cells

Resources for CD21 antibodies

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for CD21 antibodies

Publications

  1. Barrington, R. A. et al. (2005) CD21/CD19 coreceptor signaling promotes B cell survival during primary immune responses. J. Immunol. 175: 2589-2867
  2. Cherukuri, A. et al. (2001) The role of the CD19/CD21 complex in B cell processing and presentation of complement-tagged antigens. J. Immunol. 167: 163-172
  3. Tedder, TF. et al. (1984) Expression of C3d receptors during human B cell differentiation: immunofluorescence analysis with the HB-5 monoclonal antibody. J. Immunol. 133 (2): 678-683
  4. Braun, M. et al. (1998) Human B and T lymphocytes have similar amounts of CD21 mRNA, but differ in surface expression of the CD21 glycoprotein. Int. Immunol. 10: 1197-1202
  5. Stelzer GT et al. (1997) U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry 30(5): 214-230
  6. Rothe, G et al. (2012) Consensus protocol for the flow cytometric Immunophenotyping of hematopoietic malignancies. Leukemia 10(5): 877-895
  7. van Dongen, J. J. M. et al. (2012) EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26(9): 1908-1975
  8. Roberts, M. L. et al. (1996) Epstein—Barr virus binding to CD21, the virus receptor, activates resting B cells via an intracellular pathway that is linked to B cell infection. Virology 77: 3077-3085
  9. Clinical and Laboratory Standards Institute (CLSI) (2007) Clinical Flow Cytometric Analysis of Neoplastic Hematolympoid Cells, CLSI document H43-A2 (ISBN 1-56238-635-2) CLSI; Approved Guideline - Second Edition
  10. Clinical and Laboratory Standards Institute (CLSI) (2007) Enumeration of immunologically defined cell populations by flow cytometry, CLSI document H42-A2 (ISBN 1-56238-640-9) CLSI; Approved Guideline - Second Edition
  11. Reinherz, E. L. et al. (eds) Leucocyte typing II. Springer